Literature DB >> 11131272

Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus.

S Katayama1, M Inaba, T Morita, T Awata, K Shimamoto, R Kikkawa.   

Abstract

Patients with type 2 diabetes mellitus and hypertension are thought to be at high risk for cardiovascular diseases. Recent guidelines for treatment of hypertension such as the JNC VI and WHO/ISH guidelines, recommend that antihypertensive agents be strated at as low as at 130/85 mmHg and that blood pressure be lowered to less than 130/85 mmHg. Our study was designed to clarify how well and to what extent blood pressure (BP) was controlled in Japanese hypertensive patients with or without type 2 diabetes mellitus. We interviewed two hundred physicians, randomly sellected from among the members of the Japanese Society of Hypertension (JSH) (n=98) and the Japanese Diabetes Society (JDS) (n=102) and obtained information regarding five most recent cases of hypertension with (n=954 in total) and their 2 most recent cases of hypertension without diabetes (n=371 in total). The achieved BP was below 140/90 mmHg in 40.5% of non-diabetic and 38.3% of diabetic hypertensives. The percentage of patients whose BP was less than 130/85 mmHg was 10.8% in nondiabetics and 11.4% in diabetics. The average number of hypotensive agents used was 1.46 in nondiabetics and 1.52 in diabetics. Physicians prescribed more ACE inhibitors and alpha-blockers in diabetics than in nondiabetics, although Ca-antagonists were administered in more than 70% of patients irrespective of whether or not they had diabetes. In contrast, fewer beta-blockers and diuretics were administered to diabetics. These results suggest that although Japanese physicians are considering the effects of hypotensive agents on metabolism and renal function when they treat diabetic hypertensives, the achieved blood pressure in both hypertensives with and those without diabetes is insufficient, with only one of ten patients having a blood pressure less than 130/85 mmHg even among diabetics. Improved blood pressure control will therefore be needed to treat high risk groups such as patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11131272     DOI: 10.1291/hypres.23.601

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

Review 1.  Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies.

Authors:  Donna L McLean; Scot H Simpson; Finlay A McAlister; Ross T Tsuyuki
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

2.  Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.

Authors:  Shao-Chi Yang; Wei-I Tsai; Chiau-Suong Liau; Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

3.  Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.

Authors:  Chihiro Shikata; Tetsuaki Sekikawa; Nobuaki Kimura; Akira Kojima; Shingo Seki; Hisayoshi Oka; Akihiro Nishiyama; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2007

4.  Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry.

Authors:  Thomas Mengden; Uwe Ligges; Johanna Mielke; Peter Bramlage; Andrea Korzinek; Walter Sehnert
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-11       Impact factor: 3.738

5.  Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a long-term special survey.

Authors:  Tomoko Iizuka; Yasuhiro Nishikawa; Yoshihiro Mori; Natsuko Zenimura; Takuyuki Matsumoto; Katsutoshi Hiramatsu; Masahiro Komiya
Journal:  Drugs R D       Date:  2011

6.  Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.

Authors:  Hiroyuki Daikuhara; Kensaku Fukunaga; Tomie Ohshima
Journal:  Drug Des Devel Ther       Date:  2014-02-17       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.